Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham,…
17 analysts rate DYN Buy on consensus.
Consensus price target: $35.73 (+128.75% upside from $15.62)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Kersten Dirk director | Jul 27, 2026 | Sale | 256,072 | $6.53M |
| Kersten Dirk director | Jul 27, 2026 | Sale | 5,388 | $140.32K |
| Rhodes Jason P director | Jul 7, 2026 | Sale | 11,665 | $275.53K |
| Rhodes Jason P director | Jul 7, 2026 | Sale | 5,000 | $118.05K |
| Rhodes Jason P director | Jul 7, 2026 | Sale | 14,844 | $350.62K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-446.21M |
| 2024 | $0 | — | $-317.42M |
| 2023 | $0 | — | $-235.94M |
Stock data for DYN: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics